Angion Biomedica

Angion Biomedica Corp. operates as a biopharmaceutical company. The firm focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.

NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10.

Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split

NEW ORLEANS , March 9, 2023 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

ANGION BIOMEDICA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Angion Biomedica Corp - ANGN

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Angion Biomedica Corp. (NASDAQ: ANGN) and Elicio Therapeutics is fair to Angion shareholders. Under the terms of the merger agreement, Elicio shareholders will receive newly issued shares of Angion common stock and current Angion shareholders are expected to own approximately 34.5% of the newly combined company.

ANGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Angion Biomedica Corp. Is Fair to Shareholders

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Angion Biomedica Corp (“the Company”) (NasdaqGS: ANGN) with Elicio Therapeutics pursuant to which Angion shareholders are expected to own approximately 34.5% of the newly combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

ANGION BIOMEDICA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Angion Biomedica Corp - ANGN

NEW YORK , Jan. 18, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Angion Biomedica Corp. (NASDAQ: ANGN), relating to its proposed merger with Elicio Therapeutics. Under the terms of the agreement, Elicio shareholders are expected to receive new shares of ANGN, with ANGN shareholders expected to own approximately 34.5% of the combined company.

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Angion Biomedica Corp. - ANGN

Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.

Angion (ANGN) Down on Merger Agreement With Private Biotech

MILWAUKEE , Jan. 17, 2023 /PRNewswire/ -- Ademi LLP is investigating Angion (Nasdaq: ANGN) for possible breaches of fiduciary duty and other violations of law in its transaction with Elicio.  Click here to learn how to join the action https://www.ademilaw.com/case/angion-biomedica-corp or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Angion Biomedica Corp. has entered into a Fair Transaction with Elicio

Wilmington, Delaware--(Newsfile Corp. - January 17, 2023) - Rigrodsky Law, P.A. is investigating Angion Biomedica Corp. ("Angion") (NASDAQ GS: ANGN) regarding possible breaches of fiduciary duties and other violations of law related to Angion's agreement to merge with Elicio Therapeutics, Inc.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-angion-biomedica-corp. To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Angion Biomedica Corp. Merger

BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp (NASDAQ:ANGN) under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. The combined company will continue under the Elicio Therapeutics name and will focus on advancing Elicio's proprietary lymph node-targeting Amphiphile (AMP) technology to develop immunotherapies, with a focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.

Elicio Therapeutics and Angion Enter into Definitive Merger Agreement

UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that on December 15, 2022, it received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1).

Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

UNIONDALE, N.Y. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and reported its financial results for the quarter ended June 30, 2022.

Angion Provides Corporate Update and Reports Second Quarter 2022 Financial Results

UNIONDALE, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced it has commenced a process to explore and evaluate strategic options to enhance and preserve shareholder value. Angion's Board of Directors has approved engagement of Oppenheimer & Co., Inc. as the company's exclusive financial advisor to assist in this process.

Angion Announces Process to Explore Strategic Alternatives for Enhancing and Preserving Shareholder Value

Angion Biomedica Corp (NASDAQ: ANGN) has discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis and immunoglobulin A nephropathy.  The trial began enrolling.

Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why

UNIONDALE, N.Y., June 29, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced the discontinuation of JUNIPER, its Phase 2 dose-finding trial of ANG-3070, an oral tyrosine kinase inhibitor (TKI), in patients with primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN). This trial, which began enrolling patients in December 2021, is being discontinued in the interest of patient safety based upon a reassessment of the risk/benefit profile of ANG-3070 in patients with established serious kidney disease.

Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease

Mullen Automotive

PaySign Inc

Here's what you need to know about trading penny stocks on June 1st The post What to Know About Buying Penny Stocks on June 1st appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 1st

-- Ended the quarter with $73M in cash and cash equivalents sufficient to fund operations well into 2023

Angion Provides Corporate Update and Reports First Quarter 2022 Financial Results

-- The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

UNIONDALE, N.Y., May 12, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference.

Angion Announces Participation in Upcoming Investment Conference

Applied Therapeutics Inc

Bolt Biotherapeutics

Ikena Oncology

Landos Biopharma

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases

Angion Provides Corporate Update and Reports Full Year 2021 Financial Results

UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in two upcoming investment conferences.

Angion Announces Participation in Upcoming Investment Conferences

-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases

Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference

Angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint.

Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021

ST. GALLEN, Switzerland & UNIONDALE, N.Y.--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results from the exploratory phase-II GUARD trial of Angion's ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area unde

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury

-- Angion to host a conference call today at 4:30 p.m. EST

News for Angion Biomedica Stock (ANGN)